Equitable Trust Co. Buys Shares of 12,912 Boston Scientific Corporation $BSX

Equitable Trust Co. purchased a new position in Boston Scientific Corporation (NYSE:BSX) during the 1st quarter, HoldingsChannel.com reports. The firm purchased 12,912 shares of the medical equipment provider’s stock, valued at approximately $810,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of BSX. Whipplewood Advisors LLC boosted its holdings in Boston Scientific by 1,791.7% during the 1st quarter. Whipplewood Advisors LLC now owns 681 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 645 shares during the period. First Horizon Corp increased its stake in Boston Scientific by 3.2% in the first quarter. First Horizon Corp now owns 8,594 shares of the medical equipment provider’s stock worth $539,000 after purchasing an additional 266 shares during the period. Kestra Advisory Services LLC increased its stake in Boston Scientific by 2.6% in the first quarter. Kestra Advisory Services LLC now owns 211,458 shares of the medical equipment provider’s stock worth $13,269,000 after purchasing an additional 5,321 shares during the period. Granite Investment Partners LLC lifted its position in shares of Boston Scientific by 1.7% during the first quarter. Granite Investment Partners LLC now owns 60,473 shares of the medical equipment provider’s stock worth $3,795,000 after purchasing an additional 1,003 shares during the last quarter. Finally, Resona Asset Management Co. Ltd. lifted its position in shares of Boston Scientific by 2.0% during the first quarter. Resona Asset Management Co. Ltd. now owns 464,125 shares of the medical equipment provider’s stock worth $29,139,000 after purchasing an additional 9,180 shares during the last quarter. 89.07% of the stock is owned by institutional investors.

Insider Activity

In related news, Director Edward J. Ludwig purchased 3,580 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average cost of $56.68 per share, for a total transaction of $202,914.40. Following the acquisition, the director owned 25,359 shares of the company’s stock, valued at $1,437,348.12. The trade was a 16.44% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Cheryl Pegus purchased 1,770 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The stock was bought at an average cost of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares in the company, valued at approximately $99,987.30. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders have purchased 9,800 shares of company stock worth $554,012. 0.34% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts recently commented on the stock. Bank of America reduced their price target on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Mizuho reduced their target price on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating on the stock in a research report on Monday, April 13th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $55.00 price target (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. Wolfe Research lowered Boston Scientific from an “outperform” rating to a “peer perform” rating in a report on Friday, May 29th. Finally, Zacks Research cut Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $81.32.

Boston Scientific Price Performance

NYSE BSX opened at $44.67 on Friday. The company has a market cap of $66.40 billion, a PE ratio of 18.69, a P/E/G ratio of 0.86 and a beta of 0.58. The firm’s 50 day moving average price is $49.41 and its 200-day moving average price is $67.70. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. Boston Scientific Corporation has a 52-week low of $42.25 and a 52-week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts forecast that Boston Scientific Corporation will post 3.36 EPS for the current fiscal year.

Boston Scientific announced that its board has authorized a share repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to purchase up to 6.4% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.